Fayez Sarofim & Co. Large Cap Equity SMA (S:0P00003F81)
29.45
+0.91
(+3.19%)
USD |
May 31 2024
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
Maximum Management Fee | Annualized Total Returns Since Inception (Daily) | Alpha (vs Category) (3Y) | Forecasted Dividend Yield |
---|---|---|---|
Upgrade | Upgrade | Upgrade | Upgrade |
Total Market Value (Net) | Beta (vs Category) (3Y) | Max Drawdown (Since Inception) | Fwd Dividend Yield (Long) |
Upgrade | Upgrade | Upgrade | Upgrade |
Basic Info
Investment Strategy | |
The Large Cap Equity product seeks to achieve long-term capital growth by outperforming the S&P 500 across market cycles. We use a high conviction, bottom-up, fundamental approach to find industry-leading multinationals that have demonstrated superior profitability, financial flexibility, and capital stewardship and are positioned to maintain above-average earnings growth longer term. We employ a buy-and-hold investment strategy with an investment perspective of three-to-five-years. We invest in companies with $5 Billion or greater market cap. |
General | |
Security Type | Separately Managed Account |
Equity Style | Large Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | US Equity |
Broad Category | Equity |
Category Name | Large Blend |
Category Index | Russell 1000 TR USD |
Global Category Name | US Equity Large Cap Blend |
YCharts Categorization | US Large Cap Blend |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Fund Owner Firm Name | Fayez Sarofim & Company |
Prospectus Benchmark Index | |
S&P 500 TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Catherine Crain | 24.52 yrs |
Charles Sheedy | 24.52 yrs |
Christopher Sarofim | 24.52 yrs |
W. Gentry Lee | 24.52 yrs |
Alan Christensen | 18.59 yrs |
Annual Total Returns Versus Peers
As of May 31, 2024.
Asset Allocation
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
Microsoft Corp | 9.20% | 467.56 | 1.47% |
Amazon.com Inc | 5.67% | 200.00 | 1.22% |
Novo Nordisk A/S ADR | 4.34% | 142.37 | 2.52% |
Apple Inc | 4.10% | 226.34 | 2.16% |
Visa Inc Class A | 3.71% | 270.36 | 0.51% |
Alphabet Inc Class C | 3.70% | 191.96 | 2.44% |
ASML Holding NV ADR | 3.30% | 1074.48 | 0.29% |
UnitedHealth Group Inc | 3.10% | 488.01 | -0.38% |
Hess Corp | 2.97% | 146.88 | -1.56% |
Intuit Inc | 2.93% | 668.75 | 1.34% |
Fees & Availability
Fees | |
Negotiable Fee | No |
Administrative Fee | -- |
Maximum Management Fee | Upgrade |
Prospectus Custodian Fee | -- |
Trustee Fee | -- |
Purchase Details | |
Open to New Investors |
|
Open to Existing Investors |
|
Minimum Initial Investment | -- |
Minimum Subsequent Investment | -- |
Basic Info
Investment Strategy | |
The Large Cap Equity product seeks to achieve long-term capital growth by outperforming the S&P 500 across market cycles. We use a high conviction, bottom-up, fundamental approach to find industry-leading multinationals that have demonstrated superior profitability, financial flexibility, and capital stewardship and are positioned to maintain above-average earnings growth longer term. We employ a buy-and-hold investment strategy with an investment perspective of three-to-five-years. We invest in companies with $5 Billion or greater market cap. |
General | |
Security Type | Separately Managed Account |
Equity Style | Large Cap/Growth |
Fixed Income Style | -- |
Broad Asset Class | US Equity |
Broad Category | Equity |
Category Name | Large Blend |
Category Index | Russell 1000 TR USD |
Global Category Name | US Equity Large Cap Blend |
YCharts Categorization | US Large Cap Blend |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Fund Owner Firm Name | Fayez Sarofim & Company |
Prospectus Benchmark Index | |
S&P 500 TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Catherine Crain | 24.52 yrs |
Charles Sheedy | 24.52 yrs |
Christopher Sarofim | 24.52 yrs |
W. Gentry Lee | 24.52 yrs |
Alan Christensen | 18.59 yrs |
Fundamentals
Number of Holdings | Upgrade |
Stock | |
Weighted Average PE Ratio | 30.20 |
Weighted Average Price to Sales Ratio | Upgrade |
Weighted Average Price to Book Ratio | Upgrade |
Weighted Median ROE | Upgrade |
Weighted Median ROA | Upgrade |
Forecasted Dividend Yield | Upgrade |
Forecasted PE Ratio | Upgrade |
Forecasted Price to Sales Ratio | Upgrade |
Forecasted Price to Book Ratio | Upgrade |
As of March 31, 2024
Fund Details
Key Dates | |
Inception Date | 12/31/1999 |
Last Annual Report Date | 12/31/2023 |
Last Prospectus Date | -- |
Attributes | |
Index Fund | No |
Inverse Fund | No |
Leveraged Fund | No |
Fund of Funds | No |
Currency Hedged Fund | No |
Synthetic Replication Fund | No |
Has Dividend Investment Plan | No |
Socially Responsible Fund | No |